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We have reported a 27% overall anti-tumor response using
i.p. immunotherapy of advanced ovarian carcinoma with
autologous, ex vivo expanded, T lymphocytes re-targeted
with bi-specific monoclonal antibody OC/TR, combined with
soluble OC/TR and low-dose recombinant interleukin-2 (IL-
2). This treatment had no effect on extraperitoneal disease.
Therefore we studied in 13 patients whether this immuno-
therapeutic protocol resulted only in local or also in systemic
immunomodulation. The phenotype of the ex vivo expanded
lymphocytes was mainly CD31, 42, 81, 162, 562. Their OC/TR-
re-targeted cytolytic activity against Igrov-1 ovarian-carci-
noma cells was approximately as high in responders as in
non-responders. Following most therapeutic cycles, the immu-
nophenotype of lymphocytes recovered from the peritoneal
fluid was similar to that of the infused T cells (i.e., mainly
CD31, 42, 81) and they were coated with OC/TR. However,
cytolytic activity of the recovered lymphocytes against Ig-
rov-1 cells was low in direct assays, and only slightly increased
after additional in vitro re-targeting with OC/TR. Systemi-
cally, the i.p. immunotherapy resulted in a transient lympho-
penia lasting for about 7 days, low (i.e., 5 to 13 ng/ml) serum
concentrations of free, functional OC/TR, and very weak
coating of circulating T lymphocytes with OC/TR. These
peripheral-blood T lymphocytes did not exert OC/TR-re-
targeted cytolytic activity. Thus, locoregional OC/TR-re-
targeted cellular immunotherapy resulted in substantial local
immunomodulation and anti-tumor effects but virtually no
systemic immunomodulation. Int. J. Cancer 73:211–219, 1997.
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The long-term results of chemotherapy of advanced ovarian
carcinoma are disappointing because of the high frequency of
relapse. In addition, immunotherapy of ovarian cancer using
monoclonal antibodies (MAbs) or cytokines has met with only
limited successes, i.e., reduction of malignant ascites, or low
response rates of short duration (Buckman et al., 1992; Steis et al.,
1990). Adoptive immunotherapy with tumor-specific autologous
cytotoxic T lymphocytes (CTL) has thus far not been feasible due
to difficulties in generating sufficient numbers of such CTL
(Ioannides et al., 1991).
Re-targeting CTL with bi-specific monoclonal antibodies (bs-
MAbs) directed to the CD3 molecule of the T-cell-receptor
complex and a tumor-associated antigen on tumor cells combines
the cytolytic potential of in vitro-expanded T lymphocytes with the
tumor selectivity of MAbs (Van Dijk et al., 1989). This approach
has been effective in reducing or eliminating human tumors from
xenotransplanted mice (Renner et al., 1994), and has been clini-
cally effective against malignant glioma (Nitta et al., 1990),
ovarian carcinoma (Canevari et al., 1995) and malignant ascites of
adenocarcinoma (Kroesen et al., 1993).
The bs-MAb OC/TR is specific for CD3 on T lymphocytes and
for a high-affinity folate-binding protein (MOv18) which is over-
expressed by about 90% of ovarian carcinomas (Mezzanzanica et
al., 1988; Miotti et al., 1987). OC/TR triggers the specific lysis of
ovarian-carcinoma cells by in vitro-activated peripheral-blood T
lymphocytes from healthy donors and ovarian-carcinoma patients
(Lamers et al., 1992; Pupa et al., 1988). We have treated patients
with advanced ovarian carcinoma i.p. with ex vivo-activated and
-expanded autologous T lymphocytes re-targeted with OC/TR
(Canevari et al., 1995). The cellular therapy was combined with i.p.
administration of IL-2 and soluble OC/TR to sustain proliferation
and recycling of OC/TR-re-targeted cytotoxic T lymphocytes
(Blank-Voorthuis et al., 1993). We observed only local anti-tumor
effects, and no effects on systemic, i.e., extraperitoneal disease. The
absence of systemic therapeutic effects might be related to the
absence of systemic immunomodulating effects of therapy. There-
fore, we studied (i) the correlation between immunological charac-
teristics of the therapeutically used T lymphocytes and local
immunological and anti-tumor effects, and (ii) whether or not the
locoregional immunotherapy resulted in systemic immunomodula-
tion.
MATERIAL AND METHODS
Patients and treatment schedules
Immunological studies were performed in 13 patients with
advanced, non-mucinous epithelial, MOv181 ovarian carcinoma
(FIGO stage III), and with residual tumor lesions less than 2 cm
thick after debulking surgery. Eleven patients were treated with
F(ab8)2 fragments of murine bs-MAb (OC/TR) and 2 with F(ab8)2
fragments of chimeric human-mouse bs-MAb (ch-OC/TR) (War-
naar et al., 1994). The patients received i.p. infusions of ex vivo
activated, expanded, bs-MAb-re-targeted autologous T lympho-
cytes, combined with soluble bs-MAb and low-dose IL-2 according
to 3 protocols (Table I). The phase-I/II study (8 patients) is referred
to as protocol 1, the phase-II study (3 patients) as protocol 2 and the
ch-OC/TR pilot study (2 patients) as protocol 3 in this and
subsequent sections.
Activation, expansion and re-targeting of T lymphocytes
Peripheral-blood mononuclear cells (PBMC) were obtained by a
single leukapheresis 14 days before the start of the first series of
infusions of bs-MAb-re-targeted T lymphocytes, and 108 PBMC
were activated and expanded using PHA (HA16; Wellcome,
Dartford, UK) and IL-2 (Proleukin; Eurocetus, Amsterdam, The
Netherlands) as described (Canevari et al., 1995; Lamers et al.,
1992). These expanded T lymphocytes were used for the first 2
series of infusions in all 3 protocols. The remainder of the apheresis
product (2 2 3 3 108 PBMC) was cryopreserved, thawed 2 weeks
later, and served as a lymphocyte source for ex vivo expansion to
enable a third cycle of infusions (protocol 1 only). Prior to i.p.
administration, the ex vivo-activated and -expanded T lymphocytes
were re-targeted with F(ab8)2 fragments of (ch-)OC/TR (Centocor
Europe, Leiden, The Netherlands) at 1 mg per 109 viable cells by
30-min incubation at 37°C. The bs-MAb-re-targeted T lympho-
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cytes were washed to remove unbound bs-MAb during the
cell-dose-escalation cycle (protocol 1), but not during the treatment
cycles (all 3 protocols).
Immunomonitoring schedule
The day of leukapheresis was designated day 0. EDTA-anti-
coagulated venous blood samples were obtained for assessments of
absolute lymphocyte counts, peritoneal fluid and heparinized blood
samples for immunophenotyping assays and assessments of cyto-
lytic activities, and serum samples for quantification of free
functional bs-MAb at various time points before, during and after
therapy, as indicated in ‘‘Results’’.
PBMC were isolated from blood samples by Ficoll-Isopaque
density centrifugation. Serum and peritoneal-fluid samples were
cleared from cells and debris by centrifugation (1500 g for 10 min)
and stored at 280°C until further investigation. Immunophenotyp-
ing was performed on fresh PBMC and peritoneal cells at all time
points, while cytotoxicity assays were performed on cryopreserved
and thawed PBMC to allow simultaneous testing of all samples
from each patient.
Flow-cytometric immunophenotyping and detection of
cell-bound OC/TR
The following MAb mixtures were used for immunophenotyp-
ing: CD45 (anti-HLE-1/FITC) 1 CD14 (anti-Leu M3/PE), CD3
(anti-Leu 4/FITC) 1 CD56 (anti-Leu 19/PE), CD4 (anti-Leu
3ab/FITC) 1 CD8 (DAKO-CD8/PE), CD19 (anti-Leu12/FITC) 1
CD16 (anti-Leu 11c/FITC) and mouse (m) IgG1/FITC 1 mIgG1/PE
as isotype controls. The CD8 MAb was obtained from DAKO
(Glostrup, Denmark), all others from Becton Dickinson (San Jose,
CA). Detection of OC/TR bound to PBMC or peritoneal-fluid
lymphocytes was determined using goat anti-mouse (GAM) IgG1/
PE, with GAM IgG2a/PE as conjugate control (both from Southern
Biotechnology, Birmingham, AL). Absolute lymphocyte counts,
immunostaining and flow cytometry were performed as described
(Gratama et al., 1996).
Cytotoxicity assays
Cytolytic activity was determined in a standard 3-hr 51Cr-release
assay (Lamers et al., 1992). From the percentages of specific lysis
derived from 4 effector- to -target ratios (i.e., 50:1, 25:1, 12.5:1
and 6.3:1), the weighed mean of specific lysis (WMSL) was
calculated as




where SLi is the percentage of specific lysis at E:T ratio ETi, and
ETi is E:T ratio i. The WMSL expresses the average cytolytic
activity standardized at E:T ratio 5 17.7, i.e., the mean log E:T
ratio. For the bs-MAb-re-targeted cytotoxicity assay, the MOv18-
antigen-positive ovarian-carcinoma-derived cell line Igrov-1 (Be´-
nard et al., 1985) was used as target cell. Effector T lymphocytes
were pre-incubated with 200 ng/ml OC/TR F(ab8)2 at 37°C for 30
min, and OC/TR-re-targeted cytotoxicity was expressed as DIgrov,
i.e., the increase (D) of WMSL of Igrov-1 cells by OC/TR-re-
targeted effector cells relative to effector cells that had not been
re-targeted. The OKT3 hybridoma cell line, expressing membrane-
bound CD3 MAb, served as a positive target-cell control for
reversed-antibody (CD3)-dependent cellular cytotoxicity (ADCC).
The K562 erythroleukemia and Daudi Burkitt’s-lymphoma cell
lines were used as target cells for the assessment of natural-
killer(NK) and lymphokine-activated-killer(LAK) activity respec-
tively.
For the detection of functional unbound bs-MAb in serum and
peritoneal fluid, the CD31, 42, 81, TCRab1 CTL clone D11
(Bolhuis and Van de Griend, 1985) was incubated in serial dilutions
of bs-MAb (i.e., 0, 0.01, 0.1, 1, 10, 100 and 1000 ng/ml in human
AB serum), or in patient serum, for 60 min at 37°C. The D11 cells
were then washed and processed in a 3-hr 51Cr-release assay
against Igrov-1 target cells at 8 E:T ratios ranging from 50:1 to
1.25:1. Per experiment, the serial dilutions of bs-MAb were plotted
on a logarithmic scale against the corresponding WMSL value (at
E:T ratio 5 7.9:1, i.e., the mean log E:T ratio), yielding a sigmoid
standard curve. From the linear part of that curve, the concentration
of free functional bs-MAb in patient serum was determined by




The clinical anti-tumor response was investigated by laparotomy
in 12 of the 13 patients and classified according to standard WHO
criteria (Canevari et al., 1995): 2 partial remissions (PR), 1 stable
TABLE I – TREATMENT SCHEDULES
Phase/treatment cycle Day of therapy
relative to leukapheresis 1
st infusion1,2 2nd infusion1,2
Protocol 1 (Phase I/II: murine OC/TR)
I—Cell dose escalation 14 106 Ly 3 OC/TR3 1 IL-2 IL-2
15 107 Ly 3 OC/TR3 1 IL-2 IL-2
16 108 Ly 3 OC/TR3 1 IL-2 IL-2
17 109 Ly 3 OC/TR3 1 IL-2 IL-2
II—1st therapeutic cycle 20, 21, 22, 23, 24
25, 26




II—2nd therapeutic cycle 41, 42, 43, 44, 45
46, 47




Protocol 2 (Phase II: murine OC/TR)
1st therapeutic cycle 14, 15, 16, 17, 18
19, 20




2nd therapeutic cycle 21, 22, 23, 24, 25
26, 27




Protocol 3 (chimeric human/murine OC/TR)
1st therapeutic cycle 14, 15, 16, 17, 18 109 Ly 3 ch-OC/TR4 1 IL-2 ch-OC/TR 1 IL-2
2nd therapeutic cycle 21, 22, 23, 24, 25 109 Ly 3 ch-OC/TR4 1 IL-2 ch-OC/TR 1 IL-2
1The 1st infusion was administered at 12 a.m. and the 2nd infusion at 8 p.m.–2Ly 3 (ch-)OC/TR, autologous T lymphocytes loaded with
(ch-)OCTR bs-MAb; IL-2, 0.6 3 106 IU IL-2; (ch-)OC/TR, 1 mg soluble (ch-)OC/TR bs-MAb. All infusions were given in 500 ml of Ringer’s
lactate solution supplemented with 1% human serum albumin.–3Unbound OC/TR bs-MAb was removed by washing.–4Unbound (ch-)OC/TR
bs-MAb was not removed.
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disease (SD) and 5 progressive disease (PD) in protocol 1; 1
complete remission (CR), 1 PR and 1 PD in protocol 2 and 1 PR in
protocol 3. Laparotomy was not performed in the second patient in
protocol 3.
Immunophenotype and cytolytic activities of
ex vivo-expanded lymphocytes
During the 14 to 25 days of ex vivo expansion, the CD31, 42, 81,
162, 562 immunophenotype became predominant in all protocols
(Fig. 1, and data not shown). Patients treated as per protocols 2 and
3 received fewer CD31 lymphocytes than those treated as per
protocol 1 ( p 5 0.01, Wilcoxon’s test; Table II). That difference
was partly due to the fact that patients in protocol 1 were scheduled
to receive a total of 11.1 3 109 OC/TR-re-targeted lymphocytes in
3 cycles vs. 10.0 3 109 lymphocytes in 2 cycles according to
protocols 2 and 3. In addition, the ex vivo expanded lymphocytes of
3 of the 5 patients in protocols 2 and 3 contained relatively many
lymphocytes with a NK phenotype (i.e., CD32, 161, 561) and,
therefore, relatively low proportions of CD31 lymphocytes (Fig. 1,
and data not shown). The reason for the preferential expansion of
NK cells in these 3 patients was unknown; the frequencies of
CD161, 192 and CD32, 561 lymphocytes after ex vivo expansion
did not correlate with the proportions of such cells in the apheresis
products from which the cultures were initiated. The total numbers
of CD41, CD81, CD161 and CD561 lymphocytes administered to
the patients in protocols 1 vs. 2 and 3 were not significantly
different (Table II).
The CD3 MAb-dependent and OC/TR-re-targeted cytolytic
activity of the unstimulated PBMC in the apheresis products was,
as expected, similar to that observed with PBMC from healthy
donors (Fig. 1; Lamers et al., 1992). Lymphocytes derived from
fresh PBMC exerted significant levels of CD3-MAb-dependent
cytolytic activity (median WMSL 79%, range 25 to 128%) and
OC/TR-re-targeted cytolysis (DIgrov, 35%, range 5 to 86%) at the
start of the first therapeutic cycle (following 14 or 20 days of ex
vivo activation; Fig. 1). Lymphocytes derived from cryopreserved
PBMC exerted lower levels of CD3 MAb-dependent and OC/TR-
re-targeted (DIgrov) cytolytic activity at the start of the second
therapeutic cycle of protocol 1 (following 17 days of ex vivo
activation): median 52% (range 0 to 113%) and 27% (3 to 46%)
respectively. The difference between cytolytic activity exerted by
lymphocytes derived from fresh and from cryopreserved PBMC
was not significant. The NK and LAK activity of the activated and
expanded lymphocytes showed wide variation between patients
(data not shown).
The immunophenotype (data not shown) and cytolytic activity of
the ex vivo expanded lymphocytes at the first and last days of each
therapeutic cycle did not differ significantly between the 5 patients
with an anti-tumor response (CR or PR) and the 7 patients without
anti-tumor response (SD or PD). Specifically, the median (range)
WMSL of OC/TR-re-targeted cytolytic activity (DIgrov) of lympho-
cytes infused at the first and last days of each of the 2 therapeutic
cycles was 38% (6 to 58%) in responding patients and 42% (11 to
51%) in non-responding patients.
Immunophenotype and cytolytic activities of peripheral-blood and
peritoneal-fluid lymphocytes
Before treatment, most patients had lower absolute lymphocyte
counts than healthy individuals (Fig. 2). In particular, absolute
counts of CD31 (Fig. 2) and CD41 (not shown) T lymphocytes
were lower, whereas those of CD81 (Fig. 2) T, CD561, 32 and
CD161 NK, and CD191 B lymphocytes (not shown) were normal.
During the first therapeutic cycle, absolute lymphocyte counts
decreased transiently (i.e., for about 7 days). The magnitude of this
transient drop in absolute lymphocyte counts was less during the
second therapeutic cycle. Immunological assays had been sched-
uled only before and after each cycle. At these time points, absolute
counts of lymphocytes and their sub-sets did not differ significantly
from pre-treatment values (Fig. 2, and data not shown). The levels
of OC/TR-re-targeted cytolytic activity (DIgrov) by pre-treatment
PBMC were low (median 7%, range 1 to 48%), as was to be
expected from unactivated T lymphocytes (Fig. 2; Lamers et al.,
1992). Post-treatment PBMC exerted only low levels of cytolytic
activity against the Igrov-1 ovarian-carcinoma cell line in spite of
the fact that they were coated with bs-MAb (see Figs. 2, 4, and
below). In addition, the levels of OC/TR-re-targeted cytolytic
activity of PBMC after in vitro pre-incubation with 200 ng/ml
OC/TR were similarly low after each therapeutic cycle (Fig. 2).
Before immunotherapy, the proportions of peritoneal-fluid lym-
phocytes expressing T-cell markers were similar to those in blood,
i.e., approximately 75%, being CD31, with a ratio of about 1
between CD41 and CD81 sub-sets (Fig. 3, and data not shown).
The lymphocytes recovered from the peritoneal fluid following the
therapeutic cycles had an immunophenotype (i.e., CD31, 42, 81,
162, 562) similar to the ex vivo-expanded lymphocytes (Fig. 3, and
data not shown). The pre-treatment level of OC/TR-re-targeted
cytolysis (DIgrov) of intraperitoneal lymphocytes was as low
(median 6%, range 3 to 22%) as that of PBMC (Figs. 2, 3). The
lymphocytes recovered from the peritoneal fluid following the dose
escalation and therapeutic cycles exerted higher levels of OC/TR-
re-targeted cytolytic activity than those isolated from the peritoneal
fluid prior to therapy, but lower levels of OC/TR-re-targeted
cytolytic activity than ex vivo-expanded T lymphocytes (Figs. 1, 3).
Of note, post-treatment peritoneal-fluid lymphocytes exerted only
low levels of cytolytic activity against the Igrov-1 ovarian-
carcinoma cell line, in spite of the fact that they were still coated
with bs-MAb (see Figs. 3, 4, and below).
In vivo coating of peritoneal-fluid and peripheral-blood
lymphocytes with bs-MAb
The presence of bs-MAb on peritoneal-fluid lymphocytes was
visualized by a rightward shift of the majority of the lymphocyte
population in the fluorescence histogram after labeling with GAM
IgG1/PE. Data from patient 9 (protocol 2) are shown in Figure 4. A
comparison of the lower left 2 panels of Figure 4 reveals the
presence of bs-MAb on the lymphocytes recovered from the
peritoneal fluid 1 day after the first therapeutic cycle. Similarly,
placement of the marker at the foot of the peak of the GAM
IgG2a/PE conjugate control staining revealed a median of 61%
(range 9 to 85%) positive lymphocytes at the end of the first
therapeutic cycle in 10 patients (protocol 1, n 5 6; protocol 2,
n 5 2; protocol 3, n 5 2). Lymphocytes recovered from patient 9’s
peritoneal fluid at 12 hr after the last OC/TR infusion of the second
therapeutic cycle showed 51% positivity (Fig. 4, lower right panel).
She had not developed human anti-mouse antibodies (HAMA) at
detectable levels by that time, i.e., 14 days after the start of bs-MAb
and lymphocyte infusions. However, OC/TR was only barely
detectable (6 and 11%) on peritoneal-fluid lymphocytes of 2
patients in protocol 1 at the end of the second therapeutic cycle, 28
days after start of bs-MAb and lymphocyte infusions. Both patients
had developed HAMA (Lamers et al., 1995).
On peripheral-blood lymphocytes, we also detected OC/TR
during therapy. Labeling of patient 9’s PBMC with GAM/IgG1/PE
revealed a dim staining pattern after the first (day 21 relative to
leukapheresis) and during the second therapeutic cycle (day 25) as
compared with pretreatment (day 14). Lymphocyte-bound OC/TR
became undetectable 12 hr after the last OC/TR infusion (day 28;
Fig. 4, upper panels).
Serum concentrations of functional unbound bs-MAb
The bs-MAb-re-targeted CTX assay was also used to quantify
the concentrations of functional unbound (ch-)OC/TR in patient
sera. Lymphocytes derived from the CD31, 81 T-cell clone D11
were pre-incubated with patient sera before their use in a CTX
assay against Igrov-1 cells. Functional unbound OC/TR became
detectable (5 to 13 ng/ml) in sera of 3 of 4 patients in protocol 1 12
hr after the last i.p. OC/TR infusion of the first therapeutic cycle.
However, functional unbound OC/TR was no longer detectable in
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their sera 12 hr after the final i.p. OC/TR infusion of the second
therapeutic cycle. All these 4 patients had developed HAMA at the
end of the second therapeutic cycle (Lamers et al., 1995). In
contrast, functional unbound OC/TR was still detectable (8 to 9
ng/ml) in the sera of 2 patients in protocol 2 12 hr after the final i.p.
OC/TR infusion of the second therapeutic cycle. These patients did
not develop detectable HAMA until 15 to 25 days after completion
of therapy (data not shown). Functional unbound ch-OC/TR was
detectable (6 ng/ml) in 1 of the 2 patients in protocol 3 at 21⁄2 days
after the final i.p. infusion of ch-OC/TR of the first therapeutic
cycle, but not at the corresponding time point after the second
therapeutic cycle. None of the 2 patients in protocol 3 developed
HAMA (data not shown). Thus, functional unbound bs-MAb was
present in the circulation for at least 12 hr after i.p. infusion, unless
a HAMA response had developed.
DISCUSSION
I.p. immunotherapy of advanced ovarian carcinoma using autolo-
gous ex vivo-activated and -expanded T lymphocytes re-targeted
with the bs-MAb OC/TR specific for CD3 and the folate-binding
protein over-expressed by ovarian-carcinoma cells, can induce
local tumor regressions as evidenced by a 27% overall response
rate (Canevari et al., 1995). However, this locoregional treatment
had no effect on extraperitoneal disease. In view of these results,
we studied (i) the correlation between immunological characteris-
tics of the therapeutically used T lymphocytes, and local immuno-
logical and anti-tumor effects, and (ii) whether or not the locore-
gional immunotherapy resulted in systemic immunomodulation.
Although our activation and expansion protocol based on
PHA 1 IL-2 resulted in the preferential expansion of CD31, 42,
81, 162, 562 T lymphocytes, confirming our pre-clinical studies
(Lamers et al., 1992), there was considerable variation in the
numbers of NK lymphocytes (CD161, 561, 32) administered to the
patients (Table II). In addition, cytolytic activity of the expanded
lymphocytes varied over a wide range (Fig. 2). However, neither
immunophenotype (CD3, CD4, CD8, CD16, CD56) nor levels of
cytolytic activity (OC/TR-re-targeted cytotoxicity, reversed ADCC,
NK and LAK) of the infused lymphocytes correlated with an
anti-tumor response (CR or PR vs. SD or PD).
Because the growth rate of T lymphocytes levels off to zero after
4 weeks of IL-2-supported culture (Lamers et al., 1992), fresh
PBMC cultures could not produce enough lymphocytes between
days 35 and 39 of culture for the second therapeutic cycle of
protocol 1. Hence, we used cryopreserved and thawed PBMC to
generate lymphocytes for the second therapeutic cycle. The elimi-
nation of the 2-week rest period between the 2 therapeutic cycles in
protocols 2 and 3 not only enabled the generation of all lympho-
cytes required for both therapeutic cycles from a single fresh
PBMC culture, but also reduced the risk that HAMA development
would interfere with therapeutic efficacy (Lamers et al., 1995).
We studied local immunological effects of therapy by comparing
the immunophenotype and cytolytic activities of peritoneal-fluid
lymphocytes obtained before and 2 days after each series of
lymphocyte infusions. The major immunophenotype in the lympho-
cyte cultures (CD31, 42, 81) was also found among peritoneal-
fluid lymphocytes following most therapeutic cycles, but the latter
T lymphocytes did not exert levels of OC/TR-re-targeted cytolytic
activity as high as those exerted by the ex vivo-expanded T
lymphocytes prior to infusion. Moreover, post-treatment peritoneal-
fluid lymphocytes still coated with bs-MAb exerted only low levels
of cytolytic activity against ovarian-carcinoma cells. As we re-
ported earlier, OC/TR-re-targeted CTL cannot enter multiple lytic
cycles in vitro, unless newly synthesized CD3 molecules on their
surface have interacted with freshly added OC/TR bs-MAb (Blank-
Voorthuis et al., 1993). Therefore, infusions of soluble bs-MAb
were administered which resulted in i.p. bs-MAb concentrations of
approximately 1,500 ng/ml 12 hr post-infusion (data not shown).
These infusions were combined with low-dose IL-2 (0.6 3 106 IU
IL-2 per infusion) to maintain cytolytic activity of the infused T
lymphocytes and to recruit such activity from resident T lympho-
cytes. Thus, the low cytolytic activity of bs-MAb-coated peritoneal-
fluid T lymphocytes may be explained by induction of transient
anergy by their interactions with MOv181 cells (Blank-Voorthuis
et al., 1993).
One of the systemic effects of the i.p. therapy was the transient
(about 7 days) lymphopenia, especially during the first therapeutic
cycle. That effect was due to the i.p. infusions of soluble bs-MAb
and not to the infused bs-MAb-re-targeted lymphocytes and/or
IL-2, since it was not observed during the dose-escalation phase
when no soluble OC/TR was administered. A transient disappear-
FIGURE 1 – Immunophenotype and cytolytic activity of lymphocytes
during ex vivo activation and expansion. Upper 4 panels: Proportions of
lymphocytes (% of viable lymphocytes as defined by flow-cytometric
light-scatter gating) expressing CD3 or CD8 during ex vivo activation
and expansion using PHA and IL-2 (see ‘‘Material and Methods’’),
relative to treatment protocol. Lower 4 panels: Cytolytic activity of ex
vivo PHA-activated and IL-2-expanded lymphocytes against Igrov-1
ovarian-carcinoma cells without (open symbols) or with (closed
symbols) OC/TR-re-targeting of the effector cells, and against OKT3
cells (i.e., CD3-mediated or reversed ADCC) at various time points
during culture relative to treatment protocol. Results are expressed as
weighed mean of percent specific lysis at E/T ratio 17.7:1 (see
‘‘Material and Methods’’). Median values (indicated by symbols) and
ranges (indicated by bars) of 8 patients in protocol 1 (left panels) and 5
patients in protocols 2 and 3 (right panels) are shown. The symbols
below the X-axis represent the treatment cycles: open box, cell-dose
escalation (phase I); closed boxes, therapeutic cycles (phase II).
TABLE II – NUMBERS OF RE-INFUSED EX VIVO-EXPANDED LYMPHOCYTES: IMMUNOPHENOTYPICAL ANALYSIS
CD markers
Protocol 1 (n 5 8) Protocol 2 1 3(n 5 5)
Treated as per
protocol (n 5 5)1
Incomplete
treatment (n 5 3)2
Treated as per
protocol1
CD3 10.4 (10.0–10.7)3 6.9 (4.1–7.5)3 8.1 (5.2–9.9)3
CD4 3.7 (1.8–3.4) 3.1 (1.6–4.2) 1.8 (0.3–6.1)
CD8 8.7 (8.3–9.0) 3.6 (1.6–5.0) 7.0 (3.6–9.6)
CD16 0.2 (0.0–0.6) 0.2 (0.0–0.2) 1.9 (0.0–4.8)
CD56 0.1 (0.0–0.6) 0.2 (0.1–0.2) 1.7 (0.0–4.8)
Total lymphocytes 10.7 (10.1–11.1) 7.1 (4.3–7.8) 10.0 (10.0)
1Patients were considered as having been treated as per protocol if they had received .90% of the
scheduled cell number (i.e., 11.1 3 109).–2Two patients received only 70% and 39% of the planned cell
numbers, respectively, due to slow ex vivo expansion of their T lymphocytes. The third patient received
only 64% of the planned cell number because therapy had to be abrogated after the first day of the second
therapeutic cycle, due to her poor clinical condition (unrelated to the immunotherapy).–3Median (range)
number of cells infused (3109) during the entire treatment period (i.e., cell-dose escalation, 1st and 2nd
therapeutic cycle).
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ance of bs-MAb-coated lymphocytes from the circulation also
occurred between 4 and 48 hr following i.v. bolus administration of
(CD3 3 anti-tumor) bs-MAb (Kroesen et al., 1994; Tibben et al.,
1996). The low serum bs-MAb levels in our study, which ranged
between 5 and 13 ng/ml at 12 hr following the last i.p. bs-MAb
infusion, were nevertheless sufficient for in vivo coating of
peripheral-blood T lymphocytes and to cause their transient
disappearance from the circulation, probably due to their interac-
tions with MOv181 endothelial cells, but not the clinical syndrome
of massive cytokine release by activation of T lymphocytes
FIGURE 2 – Immunophenotype and cytolytic activities of peripheral-
blood lymphocytes. Absolute numbers of total lymphocytes (upper 2
panels), CD31 and CD81 lymphocyte sub-sets (middle 4 panels), and
cytolytic activities of PBMC against Igrov-1 ovarian-carcinoma cells
without (open symbols) or with (closed symbols) OC/TR-re-targeting
of effector cells (lower 2 panels) before, during and after immuno-
therapy. The shaded areas represent the normal ranges of absolute
numbers of lymphocytes and lymphocyte sub-sets as defined by the
95% confidence intervals obtained in 72 apparently healthy individu-
als. Symbols represent median values; bars indicate ranges of observa-
tions per time point. See further the legend to Figure 1.
FIGURE 3 – Immunophenotype and cytolytic activity of lymphocytes in peritoneal fluid. Proportions of CD31 (upper 2 panels) and CD81
(middle 2 panels) lymphocyte sub-sets (expressed as % of total lymphocytes), and cytolytic activities against Igrov-1 ovarian-carcinoma cells
without (open symbols) or with (closed symbols) OC/TR-re-targeting of the effector cells, by lymphocytes in peritoneal-fluid samples obtained
before, during and after immunotherapy (lower 2 panels). Symbols represent median values; bars indicate ranges of observations per time point.
See further the legend to Figure 1.
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(Kroesen et al., 1994; Tibben et al., 1996). These low serum
bs-MAb concentrations only induce bs-MAb-re-targeted cytolysis
by activated T lymphocytes such as cloned CTL (Van Ravenswaay
Claasen et al., 1993; this study) and in vitro-activated PBMC (Pupa
et al., 1988). The fact that post-treatment PBMC did not lyse
Igrov-1 ovarian-carcinoma cells in spite of their coating with
bs-MAb may be explained by anergy of their bs-MAb-retargeted
T-cell receptors (Blank-Voorthuis et al., 1993). That contention is
supported by the observation that the PBMC after each treatment
cycle did not exert significant levels of OC/TR-re-targeted cytoly-
sis even after in vitro pre-incubation with 200 ng/ml OC/TR.
Taken together, i.p. infusions of bs-MAb-targeted T lympho-
cytes, soluble bs-MAb and IL-2 resulted in significant local
immunomodulation and anti-tumor effects but virtually no sys-
temic immunomodulation. The release of soluble bs-MAb from the
peritoneal cavity resulted in serum bs-MAb concentrations that
were sufficient for in vivo coating of peripheral-blood T lympho-
cytes and their transient disappearance from the circulation, but
insufficient for their activation and induction of significant levels of
bs-MAb-re-targeted cytotoxicity. The absence of systemic immuno-
modulation, in particular bs-mAb-retargeted cytolytic activity, may
explain the lack of systemic antitumor effects of this locoregional
immunotherapeutic protocol.
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